

# Cyclotek Launches \$5M Cyclotron Facility in New Zealand



**Cyclotek Pty Ltd has announced a NZ\$5 million facility in Auckland to give New Zealanders better access to potentially life-saving diagnostic tests for cancer, neurological and coronary diseases.**


Cyclotek is Australia's largest manufacturer of the specialised radiopharmaceuticals needed to conduct Positron Emission Tomography scans – or PET scans, as they are more commonly known.

The company is fully licensed to manufacture these products, including the most commonly used tracer, 18-Fluodeoxyglucose, or FDG, to international standards. It has been Australia's major supplier since 2002 and has been supplying FDG to New Zealand since 2006.

PET is a cost-efficient, effective and non-invasive imaging technology used to examine metabolic activity in the brain, heart, liver, tumors and muscle tissues. Yet until now, access to PET scans in New Zealand has been limited due to the difficulty of obtaining fresh radiopharmaceuticals.

Due to the lack of a cyclotron, in New Zealand most patients, about 30 a week, have had to travel to Australia to benefit from the technology. The new facility will change that by ensuring FDG and a wide range of other isotopes, which make it possible to use PET scans for a greater number of procedures, are available to NZ patients whenever, and wherever, they are needed."

Known as Cyclotek Pharmaceuticals Ltd, the NZ facility will include a GE Cyclotron and a suite of Hot Cells and FDG synthesis units with quality control and



microbiology. It represents a significant investment in the New Zealand market for the company, but one that is vital.

**Cyclotek is keen to be involved in research with the New Zealand scientific and medical community, both in development of new PET radiopharmaceuticals, and their use for new applications.**

In Australia, Cyclotek was the lead organisation in the formation of the Cooperative Research Centre for Biomedical Imaging Development Ltd (CRCBID). Funded under the Commonwealth Government CRC Programme, this CRC is the largest initiative in PET radiopharmaceutical and technology development in the region. Apart from Cyclotek, participants include Peter MacCallum Cancer Centre, ANSTO, GE Healthcare, Monash University and Berthold.

Potential also exists for New Zealand researchers to participate in CRCBID projects ([www.crcbid.com.au](http://www.crcbid.com.au)).


**Continued >**



[www.cyclotek.com](http://www.cyclotek.com)

# The facility will consist of:

A GE PETtrace 16mEv Cyclotron with High Yield Targets, TracerLab MX synthesis units, COMECER Hot Cells and Automated Dispensers as well as fully-equipped QC and Microbiology Laboratories. The entire facility will feature extensive automated radiation and environmental monitoring equipment.



Production capability of the facility is sufficient to cover PET clinical service providers in both the north island and all of the south island.

Further updates on the progress of our facility will be available via our website.

The GE PETtrace Tracer Production System is a compact, automated cyclotron designed for the fast, easy, and efficient production of PET radiotracers. PETtrace operates with the efficiency required to match clinical schedules, the flexibility needed for research protocols, and the performance necessary to meet regional distribution demands.



## Enquiries

**Mr Greg Santamaria**

**M** +61 418 554 353

**E** gjsantamaria@cyclotek.com

**Mr David Krenus**

**M** +61 419 509 118

**E** dkrenus@cyclotek.com

TRACERlab MX FDG was designed to use a disposable cartridge in the synthesis process, allowing multiple back-to-back production runs for  $^{18}\text{F}$ -FDG, the most widely utilized PET tracer. The result is a remarkably high yield with little maintenance, which is perfect for high-output FDG production as well as in-house production laboratories.



[www.cyclotek.com](http://www.cyclotek.com)